LDS/Medical Tests/Epstein-Barr Virus (EBV) Early Antigen (EBV-EA) Antibody, IgG

Epstein-Barr Virus (EBV) Early Antigen (EBV-EA) Antibody, IgG

The Epstein-Barr virus (EBV) is one of the eight known herpes viruses and is the most common. It is transmitted by close contact with the saliva of an infected individual and is not known to be transmitted through the air. In the U.S. more than 90% of adults over the age of 35 will become infected with asymptomatic EBV and will test positive for the antibody. Some research suggests that EBV is possibly responsible for “chronic fatigue syndrome,” but this has not been confirmed. In teenagers and young adults, EBV can clinically manifest as infectious mononucleosis, which causes a variety of symptoms including fever, fatigue, sore throat, and swollen lymph nodes. Even though these symptoms typically resolve after a few weeks, the virus will remain dormant in certain cells for life. In rare cases, the dormant virus may reemerge and play a role in more serious diseases such as Burkitt’s lymphoma or nasopharyngeal carcinoma.

The treatment for EBV infections is supportive and treats only the symptoms. Infectious mononucleosis can last up to 4 months but will always resolve and is never fatal. When symptoms are present, a rapid screening test for infectious mononucleosis (the “mono spot” test) will be performed. If this test is negative, antibodies to EBV should be sought, including IgG and IgM to the viral capsid antigen (anti-VCA), EBV early antigen (anti-EA) and EBV nuclear antigen (anti-EBNA). IgG to the viral capsid antigen appears in the acute phase when the level of antibody peaks about 2 weeks after onset of the disease. It declines over time but will always remain detectable in the blood. IgM to the viral capsid antigen appears early but returns to undetectable levels after 4 to 6 weeks. IgG to the early antigen will appear within 2-4 weeks after onset but is undetectable after approximately 3 to 6 months. There are two types of EBV early antigens: D and R. The D and the R type EBV early antigens refer to the staining pattern present. The D pattern is seen in infectious mononucleosis and is the immunoassay that is used most frequently. EBV antibodies can be present in healthy individuals; therefore, diagnosis of EBV infection should be determined by a physician who can correlate clinical symptoms with laboratory testing.

  • Differential diagnosis of current/persistent EBV infection
  • Differential diagnosis of EBV reactivation
  • As an aid in diagnosis of infectious mononucleosis
  • As an aid in diagnosis of Burkitt's lymphoma
  • As an aid in diagnosis of nasopharyngeal carcinoma
  • As an aid in diagnosis of chronic fatigue syndrome

Positive in:

  • Current/persistent EBV infection
  • EBV reactivation
  • Infectious mononucleosis
  • Burkitt lymphoma
  • Nasopharyngeal carcinoma
  • Chronic fatigue syndrome
  • Some Lymphoproliferative diseases

Negative in:

  • Might be negative in initial/early acute infection

 <0.9 Index value (No detectable IgG antibody to EBV-EA

0.91 - 1.09 Index value (Equivocal results, testing should be repeated in 1-2 weeks)

>1.10 index value (Reactive for IgG antibody to EBV EA

 

 

Immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA). 

Serum (SST).

Stability

  • Ambient: 48 hours
  • Refrigerated: 7 days
  • Frozen: 60 days
CBC with diff, ESR, Mono spot test, EBV viral capsid antigen IgG, EBV viral capsid antigen IgM, EBV Nuclear antigen, EBV by PCR, CMV serology, HSV 1 and 2 IgG, VZV IgG.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Virus Res. 2002 Jan 30;82(1-2):109-13. [PMID: 11885937]
  • Am Fam Physician. 2004;70:1279. [PMID: 15508538]
  • Annu Rev Pathol. 2006;1:375-404. [PMID: 18039120]
  • Lancet Infect Dis. 2003 Mar;3(3):131-40. [PMID: 12614729]
  • Am J Med. 2007 Oct;120(10):911.e1-8. [PMID: 17904463]
  • In Vivo. 2007 Sep-Oct;21(5):707-13. [PMID: 18019402]
  • Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8. [PMID: 11298158]
  • Stevens, Christine Dorresteyn. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company (2010).
  • EBV early antigen (EA) ELISA II package insert. Wampole laboratories ref. 425000CE 06/2005.
  • Epstein Barr Virus and Infectious Mononucleosis. (2006, May 16). Retrieved August 28, 2010, from Center for Disease Control: http://www.cdc.gov/ncidod/diseases/ebv.htm
  • Betty Forbes, D. F. (2007). Bailey & Scott's Diagnostic Microbiology. St. Louis: Mosby Elsevier.